Kayne Anderson Rudnick Investment Management LLC Neurocrine Biosciences Inc Transaction History

Kayne Anderson Rudnick Investment Management LLC

$42 Billion
Q4 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $3,789 - $5,003	-50 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $3,550 - $4,645	49 Added 4900.0%	50 $5,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $79 - $106	1 New	1 $0
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $1,138 - $1,552	-13 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $1,129 - $1,408	13 New	13 $1,000

Others Institutions Holding NBIX

# of Institutions

655

Shares Held

96.6M

Call Options Held

282K

Put Options Held

281K

Black Rock Inc. New York, NY

14.2M
Shares

$1.61 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$1.14 Billion
0.02% of portfolio
State Street Corp Boston, MA

4.89M
Shares

$553 Million
0.03% of portfolio
Dodge & Cox San Francisco, CA

3.02M
Shares

$341 Million
0.26% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.54M
Shares

$287 Million
0.06% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.

Account